Author: itembalabantu
-
The commercial landscape of AI protein design — funding is at the $10^9 scale, but the number of approved de novo AI-designed protein drugs is zero
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All funding, valuation and milestone totals are attributed to each company’s press releases or media reports; many details cannot be independently verified and are marked as such. Vendor blog/preprint performance…
-
The space economy’s paradox — launch costs collapsed, but only one player won: SpaceX’s single vertically-integrated capture vs a thin downstream, and the series wrap-up
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All revenue, valuation and market-size figures are attributed to the filing, announcement or trade-press aggregate they come from; company claims, agency data, analyst estimates and press reports are separated inline. Marketed $/kg is…
-
The bottleneck moved — cost-to-orbit collapsed, but the real ceilings are unit economics, orbital sustainability, spectrum and demand
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. Public-company financials are attributed to SEC filings (primary); Starlink segment economics are attributed to reporting on a private company and to analyst estimates (pending post-IPO audited financials). All orbital-environment, debris and spectrum figures…
-
Space economy Part 3 — the launch-cost collapse floods downstream with imagery and bandwidth, but the bottleneck is paying demand, not supply
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All revenue, subscriber, contract and coverage figures are attributed to the relevant filing, announcement or report, and company claims, agency data and analyst estimates are labeled separately. Demonstrated service is kept distinct from…
-
LEO mega-constellations — cheap launch has arrived, but only the vertically integrated player (Starlink) has demonstrated large-scale deployment and reported segment profit; for everyone else, announced does not equal deployed
Evidence-first notes on deep tech and the space economy, at the edge of the lab and the market. Information only — not investment advice. Every subscriber count, revenue, margin and capex figure is attributed to its source, and financial figures for Starlink/SpaceX are from a reported SpaceX S-1 or analyst estimates that could not be…
-
Launch economics — the $/kg collapse is real, but the only demonstrated layer is Falcon 9 reuse; marketed price is not internal cost is not profit, Starship full-reuse economics are unproven, and rival demand rides mostly on one anchor (Amazon)
Evidence-first notes on deep tech and the space economy, at the edge of the launch pad and the market. Information only — not investment advice. All $/kg, cadence, reflight and cost figures are attributed to the company release, filing, CEO statement, analyst estimate or trade-press (secondary) they come from. Marketed price, internal cost and launch-business…
-
The space-economy landscape — the launch-cost collapse is real, but the bottleneck is the outcome layer: sustainable unit economics and downstream demand, not dollars per kilogram
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. Every launch price, subscriber count, revenue figure and constellation size is attributed to the disclosure, filing or report it comes from, and company claims, agency data and analyst estimates are kept separate. Marketed…
-
Anatomy of the “synbio winter” — the tools/DNA-synthesis model survived, the platform/biomanufacturing model foundered, and whether the winter was a science failure or a business-model failure
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All revenues, margins, valuations, layoff rates and bankruptcy facts are attributed to each company’s own reporting (SEC 8-K/10-Q, corporate press releases) or the trade press; company claims, institutional statistics and market estimates are…
-
Biofoundries and the DBTL cycle — automation and AI industrialize the design-build-test-learn loop, but do they close the “design-predictability gap” or just industrialize trial-and-error?
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. Every fold-improvement, titer and throughput figure is attributed to the specific campaign, strain, condition and source; peer-reviewed results, company self-report and marketing are labeled separately (noted inline). Descriptions of listed and defunct companies…
-
Genetic circuits and chassis engineering — where “engineering biology” meets biological reality: Cello’s 92% is a real but bounded demonstration, and the true bottleneck is design predictability, not parts availability
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All circuit-accuracy, gene-count, metabolic-burden and generation-count figures are attributed to the specific paper, strain, library and condition in which they were measured; peer-reviewed results are separated from review or secondary…
